US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

11.42

+0.43003.91%

Pre-market: 11.420.00000.00%08:19 EDT

Volume:1.37M

Turnover:15.58M

Market Cap:1.48B

PE:-5.07

High:11.67

Open:11.16

Low:10.86

Close:10.99

52wk High:28.23

52wk Low:10.83

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.83

T/O Rate:3.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.32

PE(LYR):0.00

Loading ...

Overview Company News Filings

Kailera Therapeutics announces positive results from several presentations

Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)

Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection

Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028

THOMSON REUTERS

Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection

THOMSON REUTERS

Kailera Therapeutics to Join Bernstein Insights Healthcare Investor Forum Fireside Chat

Kailera Therapeutics to Participate in September Investor Conferences

Kailera Therapeutics CTO Nur Nicholson Files Initial Beneficial Ownership Statement

Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate

Benzinga Earnings

Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million

Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027

THOMSON REUTERS

Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027

THOMSON REUTERS

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

Kailera Therapeutics Names Nur Nicholson Chief Technology Officer

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

THOMSON REUTERS

Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/KLRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":11.42,"timestamp":1790798400000,"preClose":10.99,"halted":0,"volume":1368805,"hourTrading":{"tag":"盘前","latestPrice":11.42,"preClose":11.42,"latestTime":"08:19 EDT","volume":16,"amount":182.72,"timestamp":1790857185140,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03912647861692445,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Pre-Mkt","change":0.43,"latestTime":"10-01 08:30:54 EDT","open":11.16,"high":11.665,"low":10.86,"amount":15576608.052965,"amplitude":0.073248,"askPrice":13.05,"askSize":100,"bidPrice":11.11,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":11.42,"preHourTrading":{"tag":"盘前","latestPrice":11.42,"preClose":11.42,"latestTime":"08:19 EDT","volume":16,"amount":182.72,"timestamp":1790857185140,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.42,"preClose":11.42,"latestTime":"19:30 EDT","volume":36857,"amount":420906.92,"timestamp":1790811003210,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8300615315327622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.8300615315327622,"shares":129537300,"dividePrice":0,"high":11.665,"amplitude":0.073248,"preClose":10.99,"low":10.86,"week52Low":10.83,"pbRate":"1.32","week52High":28.2271,"institutionHeld":0,"latestPrice":11.42,"committee":0.333333,"eps":-2.254252,"divideRate":0,"volume":1368805,"delay":0,"ttmEps":-2.254252,"open":11.16,"prevYearClose":16,"prevWeekClose":11.215,"prevMonthClose":11.42,"prevQuarterClose":11.42,"fiveDayClose":13.13,"twentyDayClose":16.41,"sixtyDayClose":22.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"KLRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793826000000,"name":null,"time":"Post-Mkt","dateTimestamp":1793768400000,"actualEps":null},{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-09-30","current":-5.065982,"percent":1,"low":-21.871461,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"high":-4.876108,"avg":-13.331086,"sd":5.292403,"marketCap":1424783999},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-11","current":-6.615356,"twenty":-19.448642,"median":-13.506901,"eighty":-10.353542,"marketCap":1932987209},{"date":"2026-09-18","current":-5.732421,"twenty":-19.325153,"median":-12.9728,"eighty":-8.138973,"marketCap":1674996293},{"date":"2026-09-25","current":-5.315357,"twenty":-18.99469,"median":-12.812261,"eighty":-7.882523,"marketCap":1553131238},{"date":"2026-09-30","current":-4.876108,"twenty":-18.817283,"median":-12.75669,"eighty":-7.562182,"marketCap":1424783999}],"updateTime":1790856800663},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672592167","title":"Kailera Therapeutics announces positive results from several presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2672592167","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672592167?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:55","pubTimestamp":1790852154,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-results-from-several-presentations-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-results-from-several-presentations-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","OZEM","BK4139","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672599567","title":"Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2672599567","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672599567?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851544,"startTime":"0","endTime":"0","summary":"Kailera reports Phase 1 data showing ribupatide injection exposure similar across abdomen, arm, thigh sitesKailera highlighted Phase 1 ribupatide injection data already presented at EASD 2026.Study su","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL1dD6V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BQXX3F31.USD","BK1216","IE00BN0W2T93.GBP","BCDF","SG9999002463.SGD","SG9999014005.SGD","BK4588","LU0224508324.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK1521","LU1504937902.USD","LU2226123490.SGD","SG9999010052.SGD","SG9999004220.SGD","SG9999014039.USD","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","LU2095319765.USD","SG9999010078.USD","00016","LU2226123227.USD","03121","SUHJY","LU1539696804.USD","LU2088747998.USD","LU2210150020.SGD","OZEM","LU0229494975.USD","03145","KLRA","LU2088748020.USD","NDAQ","SG9999014021.USD","LU2088747725.USD","LU0096374516.USD","80016","LU2088748293.HKD","LU0886674414.USD","IE00BQXX3C00.GBP","LU0315179316.USD","IE00BGHQF748.EUR","SG9999009997.SGD","BK4585","IE00B1G9TL16.USD","LU1316543674.SGD","IE00BSPPW651.USD","LU1163227496.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759490","title":"Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759490","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759490?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851500,"startTime":"0","endTime":"0","summary":"- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372706/0/en/kailera-therapeutics-presents-new-clinical-data-at-easd-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","IDNA","MEDX","BK4139","JDOC","KLRA","OZEM","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671851997","title":"Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671851997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671851997?lang=en_us&edition=fundamental","pubTime":"2026-09-30 23:20","pubTimestamp":1790781616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LABU","BK4139","XBI","XLV","OZEM","LU0029874061.USD","BK4588","LU0128526141.USD","BK4581","IMNM","KLRA","BK4137","BK4563","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671526206","title":"Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2671526206","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671526206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:04","pubTimestamp":1790766276,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics completes enrollment in KaiNETIC Phase 3 trials of obesity drug ribupatide injectionKailera Therapeutics completed enrollment in its global Phase 3 KaiNETIC program testing once-w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL5QjnhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4588","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","BCDF","LU2210149790.SGD","LU2095319765.USD","KLRA","NDAQ","OZEM","SG9999014013.SGD","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671206861","title":"Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2671206861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671206861?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA31K6D5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671026205","title":"Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2671026205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671026205?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA31K6D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607217","title":"Kailera Therapeutics to Join Bernstein Insights Healthcare Investor Forum Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607217?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556482,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics to join Bernstein Insights healthcare investor forum fireside chatKailera Therapeutics will join Bernstein Insights: Healthcare Leaders and Disruptors forum on Sept. 23, 2026 at 9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL449TLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","BK4139","BK4127","BK4588","NDAQ","IE00BQXX3F31.USD","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014005.SGD","KLRA","SF","SG9999014021.USD","IE00BGHQF748.EUR","BCDF","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","OZEM","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667360705","title":"Kailera Therapeutics to Participate in September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2667360705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667360705?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Sept.  16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/16/3363053/0/en/kailera-therapeutics-to-participate-in-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","JDOC","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666125553","title":"Kailera Therapeutics CTO Nur Nicholson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666125553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666125553?lang=en_us&edition=fundamental","pubTime":"2026-09-10 07:23","pubTimestamp":1788996216,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics CTO Nur Nicholson files initial beneficial ownership statementKailera Therapeutics named Nur Nicholson as chief technology officer in an initial SEC ownership filing dated Aug. 31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL2NN1R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659818171","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818171?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:10","pubTimestamp":1786579809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on P3 Health Partners (PIII) and Kailera Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","BK4137","BK4585","BK4196","OZEM","LABU","KLRA","LU0029874061.USD","BK4581","LU0128526141.USD","XBI","PIII","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659850186","title":"Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659850186","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659850186?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:22","pubTimestamp":1786573367,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryKailera Therapeutics IncKLRA.OQreported a quarterly adjusted loss of $1.09 per share for the quarter ended June","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4492B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188516","title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188516","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188516?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:39","pubTimestamp":1786567145,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61160351/kailera-therapeutics-q2-eps-1-09-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659074999","title":"Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659074999","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659074999?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565148,"startTime":"0","endTime":"0","summary":"Kailera Q2 FY26 net loss widens to $111.31 million; R&D expenses climb to $101.06 millionKailera posted a net loss of USD 111.31 million, widening from USD 28.95 million a year earlier.R&D expenses mo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbzlZ13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","KLRA","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","LU0314104364.USD","IE00BKPKM429.USD","OZEM","SG9999014021.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659670188","title":"Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659670188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659670188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659605188","title":"Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659605188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659605188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659290711","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659290711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659290711?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992804","title":"Kailera Therapeutics Names Nur Nicholson Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992804?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:05","pubTimestamp":1786446310,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics names Nur Nicholson chief technology officerKailera Therapeutics named Nur Nicholson chief technology officer, effective Aug. 31, 2026.Role centers on scaling manufacturing and su","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2PFshn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","IE00B19Z9Z06.USD","LU0889565916.HKD","SG9999014005.SGD","BMED","BK4588","IE00B64PRP62.GBP","LU2095319765.USD","BK4532","SG9999014039.USD","PBE","KLRA","OZEM","SG9999014021.USD","IE00B19Z9P08.USD","LU2210150020.SGD","BK4139","BCDF","IE00B3QW5Z07.USD","LU0234570918.USD","BK4533","BIIB","LU0314104364.USD","LU2210149790.SGD","LU0320765992.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","BK4585","LU0109394709.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999445","title":"Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999445","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999445?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUAC13XLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957199","title":"Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957199","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957199?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:27","pubTimestamp":1786400825,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc <KLRA.OQ> expected to post a loss of75cents a share - Earnings PreviewKailera Therapeutics IncKLRA.OQKLRA.Ois expected to  report resultson August 12 for the period ending Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44727M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}]}}